Histogenics, now operating as Ocugen, focuses on developing innovative therapies for rare eye diseases using small molecules, biologics, and gene therapies. Their pipeline includes OCU300 for ocular graft versus host disease, OCU310 for dry eye disease, and OCU400 for inherited retinal diseases. They are also working on biologic therapies for macular degeneration, diabetic macular edema, and retinitis pigmentosa. Additionally, Histogenics is a regenerative medicine company specializing in musculoskeletal conditions, with their flagship product NeoCart® offering an alternative to joint replacement for cartilage damage in the knee.